Skip to main content
Journal cover image

Longitudinal follow-up study: effect of psychological co-morbidity on the prognosis of inflammatory bowel disease.

Publication ,  Journal Article
Fairbrass, KM; Gracie, DJ; Ford, AC
Published in: Alimentary pharmacology & therapeutics
August 2021

Psychological co-morbidity is more common in patients with inflammatory bowel disease (IBD), compared with the general population, but little is known about the cumulative effect of increasing psychological burden on disease behaviour.To examine the effect of psychological co-morbidity on inflammatory bowel disease in a longitudinal follow-up study.We collected complete demographic, symptom and psychological co-morbidity data (anxiety, depression and somatisation scores) at baseline from adults with IBD in biochemical remission (faecal calprotectin <250 µg/g). Objective markers of disease activity, including glucocorticosteroid prescription or flare of disease activity, escalation of therapy, hospitalisation or intestinal resection, were reviewed ≥2 years of follow-up. We performed multivariate Cox regression, controlling for patient characteristics and follow-up duration, to examine cumulative effect of psychological co-morbidities on subsequent IBD behaviour.Among 218 participants, 48 (22.0%) had one, 13 (6.0%) two and nine (4.1%) three psychological co-morbidities at baseline. Following multivariate Cox regression analysis, glucocorticosteroid prescription or flare, and escalation of medical therapy were significantly higher among those with two (hazard ratio [HR] = 3.18; 95% confidence interval [CI] 1.44-7.02, and HR = 2.48; 95% CI 1.03-5.93, respectively) or three (HR = 3.53; 95% CI 1.26-9.92, and HR = 8.19; 95% CI 2.88-23.23, respectively) psychological co-morbidities. Occurrence of at least one endpoint of interest was significantly higher with increasing psychological co-morbidity (HR = 1.74; 95% CI 1.07-2.82 for one, HR = 2.47; 95% CI 1.12-5.46 for two and HR = 4.93; 95% CI 1.84-13.17 for three psychological co-morbidities).Individuals with IBD in biochemical remission experienced a worse disease course with increasing psychological co-morbidity at baseline.

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Alimentary pharmacology & therapeutics

DOI

EISSN

1365-2036

ISSN

0269-2813

Publication Date

August 2021

Volume

54

Issue

4

Start / End Page

441 / 450

Related Subject Headings

  • Prognosis
  • Morbidity
  • Leukocyte L1 Antigen Complex
  • Inflammatory Bowel Diseases
  • Humans
  • Gastroenterology & Hepatology
  • Follow-Up Studies
  • Comorbidity
  • Adult
  • 3214 Pharmacology and pharmaceutical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Fairbrass, K. M., Gracie, D. J., & Ford, A. C. (2021). Longitudinal follow-up study: effect of psychological co-morbidity on the prognosis of inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 54(4), 441–450. https://doi.org/10.1111/apt.16454
Fairbrass, Keeley M., David J. Gracie, and Alexander C. Ford. “Longitudinal follow-up study: effect of psychological co-morbidity on the prognosis of inflammatory bowel disease.Alimentary Pharmacology & Therapeutics 54, no. 4 (August 2021): 441–50. https://doi.org/10.1111/apt.16454.
Fairbrass KM, Gracie DJ, Ford AC. Longitudinal follow-up study: effect of psychological co-morbidity on the prognosis of inflammatory bowel disease. Alimentary pharmacology & therapeutics. 2021 Aug;54(4):441–50.
Fairbrass, Keeley M., et al. “Longitudinal follow-up study: effect of psychological co-morbidity on the prognosis of inflammatory bowel disease.Alimentary Pharmacology & Therapeutics, vol. 54, no. 4, Aug. 2021, pp. 441–50. Epmc, doi:10.1111/apt.16454.
Fairbrass KM, Gracie DJ, Ford AC. Longitudinal follow-up study: effect of psychological co-morbidity on the prognosis of inflammatory bowel disease. Alimentary pharmacology & therapeutics. 2021 Aug;54(4):441–450.
Journal cover image

Published In

Alimentary pharmacology & therapeutics

DOI

EISSN

1365-2036

ISSN

0269-2813

Publication Date

August 2021

Volume

54

Issue

4

Start / End Page

441 / 450

Related Subject Headings

  • Prognosis
  • Morbidity
  • Leukocyte L1 Antigen Complex
  • Inflammatory Bowel Diseases
  • Humans
  • Gastroenterology & Hepatology
  • Follow-Up Studies
  • Comorbidity
  • Adult
  • 3214 Pharmacology and pharmaceutical sciences